Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advaxis, Inc.
Advaxis Scientific Founder Published in Prestigious Peer-Reviewed Journal of Immunology
May 26th, 2009
Dr. Yvonne Paterson (University of Pennsylvania), scientific founder of Advaxis, Inc. (OTCBB: ADXS) and members of her laboratory have a recently published work in the peer-reviewed Journal of Immunology on a new anti-angiogenic cancer vaccine (Seavey et al . J.I., 2009. 182:5537-46). This agent uses Advaxis proprietary technology to deliver the antigen VEGF-2 (aka fetal liver kinase-1) fused to a non-hemolytic form of the bacterial adjuvant Listeriolysin-O via a bioengineered strain of living Listeria monocytogenes. As reported in the paper, “Lm-Listeriolysin-O-fetal liver kinase-1 was able to eradicate some established breast tumors, reduce micro-vascular density in...
Source: Cancer Weekly (2009-05-26)
|
